Mol Oncol

ISSN	1878-0261
ISSN-L	1574-7891
IUID	3cf12452f6a9498d8ccdfbf2917e60ce
Modified	2020-11-27T13:12:57.795Z
Created	2018-12-05T08:26:33.517Z

Year 2025

PubMed DOI Crossref

Determination of ADP/ATP translocase isoform ratios in malignancy and cellular senescence.

Liblova Z, Maurencova D, Salovska B, ..., Vajrychova M, Hodny Z

Mol Oncol 19 (9) 2619-2647 [2025-09-00; online 2025-04-27]

Year 2024

PubMed DOI Crossref

The one-carbon metabolic enzyme MTHFD2 promotes resection and homologous recombination after ionizing radiation.

Marttila P, Bonagas N, Chalkiadaki C, ..., Mortusewicz O, Helleday T

Mol Oncol 18 (9) 2179-2195 [2024-09-00; online 2024-03-27]

PubMed DOI Crossref

Combining VPS34 inhibitors with STING agonists enhances type I interferon signaling and anti-tumor efficacy.

Yu Y, Bogdan M, Noman MZ, ..., De Milito A, Janji B

Mol Oncol 18 (8) 1904-1922 [2024-08-00; online 2024-03-20]

PubMed DOI Crossref

High-content screening of drug combinations of an mPGES-1 inhibitor in multicellular tumor spheroids leads to mechanistic insights into neuroblastoma chemoresistance.

Zaghmi A, Aybay E, Jiang L, ..., Seashore-Ludlow B, Larsson K

Mol Oncol 18 (2) 317-335 [2024-02-00; online 2023-08-21]

PubMed DOI Crossref

Strategies to decrease inequalities in cancer therapeutics, care and prevention: Proceedings on a conference organized by the Pontifical Academy of Sciences and the European Academy of Cancer Sciences, Vatican City, February 23-24, 2023.

Ringborg U, von Braun J, Celis J, ..., Weiderpass E, Yang H

Mol Oncol 18 (2) 245-279 [2024-02-00; online 2024-01-22]

Year 2023

PubMed DOI Crossref

Glioblastoma stem cells express non-canonical proteins and exclusive mesenchymal-like or non-mesenchymal-like protein signatures.

Babačić H, Galardi S, Umer HM, ..., Ciafrè SA, Pernemalm M

Mol Oncol 17 (2) 238-260 [2023-02-00; online 2023-01-16]

Year 2022

PubMed DOI Crossref

Emerging concepts in drug discovery for cancer therapy.

Murga M, Fernandez-Capetillo O

Mol Oncol 16 (21) 3757-3760 [2022-11-00; online 2022-11-03]

PubMed DOI Crossref

Targeting the DNA damage response and repair in cancer through nucleotide metabolism.

Helleday T, Rudd SG

Mol Oncol 16 (21) 3792-3810 [2022-11-00; online 2022-05-28]

PubMed DOI Crossref

TGFβ selects for pro-stemness over pro-invasive phenotypes during cancer cell epithelial-mesenchymal transition.

Tsubakihara Y, Ohata Y, Okita Y, ..., Heldin CH, Moustakas A

Mol Oncol 16 (12) 2330-2354 [2022-06-00; online 2022-04-10]

Mikael Sellin SciLifeLab Fellow

PubMed DOI Crossref

Dual inhibition of TGF-β and PD-L1: a novel approach to cancer treatment.

Gulley JL, Schlom J, Barcellos-Hoff MH, ..., Dussault I, Moustakas A

Mol Oncol 16 (11) 2117-2134 [2022-06-00; online 2022-01-04]

PubMed DOI Crossref

E-cadherin is a robust prognostic biomarker in colorectal cancer and low expression is associated with sensitivity to inhibitors of topoisomerase, aurora, and HSP90 in preclinical models.

Bruun J, Eide PW, Bergsland CH, ..., Lothe RA, Pellinen T

Mol Oncol 16 (12) 2312-2329 [2022-06-00; online 2021-12-26]

PubMed DOI Crossref

NOX4 regulates TGFβ-induced proliferation and self-renewal in glioblastoma stem cells.

García-Gómez P, Golán I, S Dadras M, ..., Carreras-Puigvert J, Caja L

Mol Oncol 16 (9) 1891-1912 [2022-05-00; online 2022-03-14]

PubMed DOI Crossref

Cannabidiol-induced activation of the metallothionein pathway impedes anticancer effects of disulfiram and its metabolite CuET.

Buchtova T, Skrott Z, Chroma K, ..., Bartek J, Mistrik M

Mol Oncol 16 (7) 1541-1554 [2022-04-00; online 2021-10-26]

PubMed DOI Crossref

PRRX1 induced by BMP signaling decreases tumorigenesis by epigenetically regulating glioma-initiating cell properties via DNA methyltransferase 3A.

Tanabe R, Miyazono K, Todo T, ..., Westermark B, Heldin CH

Mol Oncol 16 (1) 269-288 [2022-01-00; online 2021-07-16]

Year 2021

PubMed DOI Crossref

Combined RNA/tissue profiling identifies novel Cancer/testis genes.

Jamin SP, Hikmet F, Mathieu R, ..., Chalmel F, Primig M

Mol Oncol 15 (11) 3003-3023 [2021-11-00; online 2021-06-23]

PubMed DOI Crossref

The Porto European Cancer Research Summit 2021.

Ringborg U, Berns A, Celis JE, ..., Wren A, Zitvogel L

Mol Oncol 15 (10) 2507-2543 [2021-10-00; online 2021-09-13]

PubMed DOI Crossref

High-throughput proteomics of breast cancer interstitial fluid: identification of tumor subtype-specific serologically relevant biomarkers.

Terkelsen T, Pernemalm M, Gromov P, ..., Papaleo E, Gromova I

Mol Oncol 15 (2) 429-461 [2021-02-00; online 2021-01-04]

Year 2020

PubMed DOI Crossref

Evaluation of the chemopreventive potentials of ezetimibe and aspirin in a novel mouse model of gallbladder preneoplasia.

Rosa L, Lobos-González L, Muñoz-Durango N, ..., Espinoza JA, Roa JC

Mol Oncol 14 (11) 2834-2852 [2020-11-00; online 2020-09-17]

PubMed DOI Crossref

Aberrantly elevated suprabasin in the bone marrow as a candidate biomarker of advanced disease state in myelodysplastic syndromes.

Pribyl M, Hubackova S, Moudra A, ..., Bartek J, Hodny Z

Mol Oncol 14 (10) 2403-2419 [2020-10-00; online 2020-08-11]

Year 2019

PubMed DOI Crossref

Interferon-regulated suprabasin is essential for stress-induced stem-like cell conversion and therapy resistance of human malignancies.

Hubackova S, Pribyl M, Kyjacova L, ..., Bartek J, Hodny Z

Mol Oncol 13 (7) 1467-1489 [2019-07-00; online 2019-06-10]

PubMed DOI Crossref

BCG-induced cytokine release in bladder cancer cells is regulated by Ca2+ signaling.

Ibarra C, Karlsson M, Codeluppi S, ..., Miyakawa A, Uhlén P

Mol Oncol 13 (2) 202-211 [2019-02-00; online 2018-12-13]

Year 2018

PubMed DOI Crossref

Prognostic, predictive, and pharmacogenomic assessments of CDX2 refine stratification of colorectal cancer.

Bruun J, Sveen A, Barros R, ..., Almeida R, Lothe RA

Mol Oncol 12 (9) 1639-1655 [2018-09-00; online 2018-08-15]

Affiliated researcher

PubMed DOI Crossref

A fine-needle aspiration-based protein signature discriminates benign from malignant breast lesions.

Franzén B, Kamali-Moghaddam M, Alexeyenko A, ..., Landegren U, Lewensohn R

Mol Oncol 12 (9) 1415-1428 [2018-09-00; online 2018-08-09]

Affiliated researcher

PubMed DOI Crossref

Genomewide binding of transcription factor Snail1 in triple-negative breast cancer cells.

Maturi V, Morén A, Enroth S, Heldin CH, Moustakas A

Mol Oncol 12 (7) 1153-1174 [2018-06-00; online 2018-05-21]

Affiliated researcher

Year 2017

PubMed DOI Crossref

Bioinformatory-assisted analysis of next-generation sequencing data for precision medicine in pancreatic cancer.

Malgerud L, Lindberg J, Wirta V, ..., Grönberg H, Löhr JM

Mol Oncol 11 (10) 1413-1429 [2017-10-00; online 2017-08-08]

Affiliated researcher

PubMed DOI Crossref

Drug sensitivity and resistance testing identifies PLK1 inhibitors and gemcitabine as potent drugs for malignant peripheral nerve sheath tumors.

Kolberg M, Bruun J, Murumägi A, ..., Kallioniemi O, Lothe RA

Mol Oncol 11 (9) 1156-1171 [2017-09-00; online 2017-07-05]

Affiliated researcher

PubMed DOI Crossref

Replication stress, DNA damage signalling, and cytomegalovirus infection in human medulloblastomas.

Bartek J, Fornara O, Merchut-Maya JM, ..., Söderberg Naucler C, Bartkova J

Mol Oncol 11 (8) 945-964 [2017-08-00; online 2017-06-17]

Affiliated researcher

PubMed DOI Crossref

Epithelial-mesenchymal transition in cancer.

Moustakas A, de Herreros AG

Mol Oncol 11 (7) 715-717 [2017-07-00; online 2017-07-06]

Year 2016

PubMed DOI Crossref

DNA damage signalling barrier, oxidative stress and treatment-relevant DNA repair factor alterations during progression of human prostate cancer.

Kurfurstova D, Bartkova J, Vrtel R, ..., Bouchal J, Bartek J

Mol Oncol 10 (6) 879-894 [2016-06-00; online 2016-03-03]

Affiliated researcher

Year 2015

PubMed DOI Crossref

Detection of glyco-mucin profiles improves specificity of MUC16 and MUC1 biomarkers in ovarian serous tumours.

Ricardo S, Marcos-Silva L, Pereira D, ..., Lunet N, David L

Mol Oncol 9 (2) 503-512 [2015-02-00; online 2014-10-22]

Year 2014

PubMed DOI Crossref

Garbage in, garbage out: a critical evaluation of strategies used for validation of immunohistochemical biomarkers.

O'Hurley G, Sjöstedt E, Rahman A, ..., Gallagher WM, Lindskog C

Mol Oncol 8 (4) 783-798 [2014-06-00; online 2014-03-21]

Year 2011

PubMed DOI Crossref

The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.

Helleday T

Mol Oncol 5 (4) 387-393 [2011-08-00; online 2011-07-22]